- Home
- FOA vs ACRS Comparison
FOA vs ACRS Comparison
Compare FOA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- ACRS
- Stock Information
- Founded
- FOA 2013
- ACRS 2012
- Country
- FOA United States
- ACRS United States
- Employees
- FOA N/A
- ACRS N/A
- Industry
- FOA Finance Companies
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- ACRS Health Care
- Exchange
- FOA Nasdaq
- ACRS Nasdaq
- Market Cap
- FOA 143.7M
- ACRS 132.0M
- IPO Year
- FOA N/A
- ACRS 2015
- Fundamental
- Price
- FOA $19.37
- ACRS $2.34
- Analyst Decision
- FOA Strong Buy
- ACRS Hold
- Analyst Count
- FOA 2
- ACRS 4
- Target Price
- FOA $17.00
- ACRS $1.00
- AVG Volume (30 Days)
- FOA 49.1K
- ACRS 1.2M
- Earning Date
- FOA 11-06-2024
- ACRS 11-06-2024
- Dividend Yield
- FOA N/A
- ACRS N/A
- EPS Growth
- FOA N/A
- ACRS N/A
- EPS
- FOA 12.25
- ACRS N/A
- Revenue
- FOA $719,526,000.00
- ACRS $27,079,000.00
- Revenue This Year
- FOA N/A
- ACRS N/A
- Revenue Next Year
- FOA N/A
- ACRS N/A
- P/E Ratio
- FOA $1.47
- ACRS N/A
- Revenue Growth
- FOA 3011.46
- ACRS 26.35
- 52 Week Low
- FOA $4.10
- ACRS $0.77
- 52 Week High
- FOA $23.48
- ACRS $2.72
- Technical
- Relative Strength Index (RSI)
- FOA 69.04
- ACRS 76.82
- Support Level
- FOA $17.05
- ACRS $2.09
- Resistance Level
- FOA $23.48
- ACRS $2.68
- Average True Range (ATR)
- FOA 2.18
- ACRS 0.26
- MACD
- FOA 0.63
- ACRS 0.07
- Stochastic Oscillator
- FOA 59.38
- ACRS 80.76
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to an range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.